BusinessActinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology PlatformBy Nasdaq OMXNov 14, 2017, 1:01 PM UTC
BusinessActinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail RobozBy Nasdaq OMXNov 13, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology PlatformBy Nasdaq OMXNov 1, 2017, 1:05 PM UTC
BusinessActinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-BBy Nasdaq OMXOct 25, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at BIO Investor ForumBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid LeukemiaBy Nasdaq OMXOct 4, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council MeetingBy Nasdaq OMXSep 20, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual MeetingBy Nasdaq OMXSep 13, 2017, 11:30 AM UTC
